Skip to navigation Skip to content
Masterclass Hub
  • Twitter
  • LinkedIn
  • Home
    • About
    • Objectives
    • Why Join
    • Testimonials
  • 2022 Series
    • Up-coming Events
    • On-Demand Events
      • Collaborating on payment models to unlock the potential of multi-indication therapies.
      • Severity in value assessment: from principle to practice
    • Contributors
  • Knowledge Hub
  • On-demand tickets
    • 2021
      • About 2021 Series
      • On-demand tickets
      • Contributors
      • Knowledge Hub
  • Sponsorship
  • About
    • About OHE
    • Events
  • Login
  • Home
    • About
    • Objectives
    • Why Join
    • Testimonials
  • 2022 Series
    • Up-coming Events
    • On-Demand Events
      • Collaborating on payment models to unlock the potential of multi-indication therapies.
      • Severity in value assessment: from principle to practice
    • Contributors
  • Knowledge Hub
  • On-demand tickets
    • 2021
      • About 2021 Series
      • On-demand tickets
      • Contributors
      • Knowledge Hub
  • Sponsorship
  • About
    • About OHE
    • Events
  • Login
  • £0.00 0 items

Category: Consulting report

Search the Knowledge Hub

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Henderson N., Errea M., Skedgel C. and Jofre-Bonet, M.
  • #Consulting report,
  • #Innovation for Small Populations,

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Sampson, C. and Garau, M.
  • #Consulting report,
  • #Innovation for Small Populations,

Multi-Criteria Decision Analysis to Value Orphan Medicines

Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A.
  • #Consulting report,
  • #Innovation for Small Populations,

Establishing a Reasonable Price for an Orphan Drug

Berdud, M., Drummond, M.F., and Towse, A.
  • #Consulting report,
  • #Innovation for Small Populations,

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Towse, A. and Garau, M.
  • #Consulting report,
  • #Innovation for Small Populations,

Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

Mestre-Ferrandiz, J., Garau, M., O'Neill, P. and Sussex, J.
  • #Consulting report,
  • #Innovation for Small Populations,

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M.
  • #Consulting report,
  • #Innovation for Small Populations,

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Henderson, N., Firth, I., Errea, M., Skedgel, C. and Jofre-Bonet, M.
  • #Consulting report,
  • #Innovation for Small Populations,

Making Outcome-Based Payment a Reality in the NHS

Cole, A., Cubi-Molla, P., Pollard, J., Sim, D., Sullivan, R., Sussex, J. and Lorgelly, P.
  • #Adaptive Pathways,
  • #Consulting report,

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

Marsden, G. and Towse, A.
  • #Adaptive Pathways,
  • #Consulting report,

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M.
  • #Adaptive Pathways,
  • #Consulting report,
  • #orphan medicine,

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

 Marina Rodes Sanchez, Nadine Henderson and Lotte Steuten
  • #Adaptive Pathways,
  • #Cancer,
  • #Consulting report,
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Brassel, S., Neri, M. and Steuten, L.
  • #Consulting report,
  • #Exploring Value,
  • #The broader value of vaccines,
The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Brassel, S. and Steuten, L.
  • #Consulting report,
  • #Exploring Value,
  • #The broader value of vaccines,
Realising the Broader Value of Vaccines in the UK

Realising the Broader Value of Vaccines in the UK

Brassel, S., Neri, M., O’Neill, P. and Steuten, L.
  • #Consulting report,
  • #Exploring Value,
  • #The broader value of vaccines,

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Hampson, G., Mott, D., Devlin, N. and Shah, K
  • #Consulting report,
  • #Discrete Choice Experiment,
  • #Patient Voice,

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N.
  • #Consulting report,
  • #Patient Outcomes,
The Many Faces of Innovation

The Many Faces of Innovation

Mestre-Ferrandiz, J., Mordoh, A. and Sussex, J.
  • #Consulting report,
  • #Exploring Value,
  • #Value frameworks,
The Many Faces of Innovation

The Many Faces of Innovation

OHE Consulting
  • #Consulting report,
  • #Exploring Value,
  • #Value frameworks,
OHE logo
Bespoke events:
events@ohe.org
  • Terms and Conditions
  • Privacy Policy
  • Contact us
  • Get Technical Assistance

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT.

Get Technical Assistance